Goldman Sachs raised the firm’s price target on Roivant Sciences (ROIV) to $16 from $14 and keeps a Buy rating on the shares. The analyst cites positive data from Phase 1 single ascending dose and initial multiple ascending dose data of Innmunovant’s (IMVT) IMVT-1402, which reinforce the agent’s clean profile and potential for best-in-class IgG reductions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ROIV:
- Immunovant announces $300M offering of common stock
- Unusually active option classes on open September 26th
- Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
- Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants
- Roivant Sciences reports Q1 EPS (38c), consensus (30c)